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Abstract
Background: Irinotecan is approved and widely administered to metastatic colorectal cancer (mCRC) patients;
however, it can cause severe toxicities including neutropenia and diarrhea. The polymorphisms of genes encoding
drug-metabolizing enzymes can play a crucial role in the increased susceptibility of cancer patients to chemotherapy
toxicity. Therefore, we plan to explore the effect of the genetic polymorphism of uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) for irinotecan detoxification in mCRC patients. This trial will compare the clinical
outcomes and side effects observed in mCRC patients treated with bevacizumab plus 5-fluorouracil/leucovorin/
irinotecan (FOLFIRI) with and without UGT1A1 genotyping and irinotecan dose escalation. A total of 400 mCRC patients
were randomized into a study group and a control group.
Methods/Design: This trial is a prospective, multicenter, randomized clinical trial comparing UGT1A1 promoter
polymorphism for irinotecan dose escalation in mCRC patients administered with bevacizumab plus FOLFIRI as the
first-line setting. The enrolled patients were randomly assigned to one of two groups, a study group and a control
group, on the basis of receiving UGT1A1 genotyping or not. The study group receive a biweekly FOLFIRI regimen, with
irinotecan dose escalation based on UGT1A1 genotyping; whereas the control group receive the conventional biweekly
FOLFIRI regimen without UGT1A1 genotyping. The clinicopathological features, response rates, toxicity, and
progression-free survival or overall survival will be compared between the two groups.
Discussion: Patients with mCRC undergoing UGT1A1 genotyping may receive escalated doses of irinotecan for a
potentially more favorable clinical response and outcome, in addition to comparable toxicities. Such personalized
medicine based on genotyping may be feasible for clinical practice.
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Rationale for the trial
Metastatic lesions are reported in 20–25 % of patients
with an initial diagnosis of colorectal cancer (CRC) and in
up to 50 % of patients with an eventful treatment course.
Because of the limited treatment response of metastatic
colorectal cancer (mCRC) patients to 5-fluorouracil (5-
FU) combined with leucovorin (LV), other therapeutic
agents with different mechanisms can be considered, such
as irinotecan, a potent inhibitor of topoisomerase I in-
volved in unwinding the DNA during replication [1–4].
Bevacizumab, the first antiangiogenic agent approved for
cancer treatment, is a humanized monoclonal antibody
that inhibits tumor angiogenesis by blocking vascular
endothelial growth factor [5, 6].Previous trials
Infusional FU or LV plus an irinotecan-based regimen
(FOLFIRI) with bevacizumab has been widely used as a
first-line treatment for patients with mCRC [1]. Recently,
a prospective analysis of uridine diphosphate glucuronosyl
transferase 1A1 (UGT1A1) genotyping was reported to
guide irinotecan dose escalation (FOLFIRI regimen) in
combination with biweekly bevacizumab in a first-line
treatment setting of mCRC patients and resulted in satis-
factory therapeutic outcomes clinically [7]. Our previous
retrospective study showed that the clinical response rate
of patients with mCRC treated with FOLFIRI plus bevaci-
zumab under UGT1A1 genotyping and irinotecan dose
escalation was significantly higher than that of those with-
out UGT1A1 genotyping and dose escalation [8]. The two
groups (conventional and escalated doses of irinotecan
after UGT1A1 genotyping) did not differ statistically
regarding receiving prior surgery or the subsequent
administration of 5-FU/LV/oxaliplatin adjuvant chemo-
therapy. The clinical response rate was significantly higher
in the mCRC patients receiving UGT1A1 genotyping and
irinotecan dose escalation in advance than in those not
receiving genotyping. The two groups did not differ
significantly in grade 3/4 adverse events. Furthermore, the
progression-free survival (PFS) was significantly higher in
the patients with mCRC who received UGT1A1 genotyp-
ing and irinotecan dose escalation before systemic treat-
ment than in those who did not receive prospective
UGT1A1 genotyping, with a median PFS of 12.2 months
versus 9.4 months [8].A prodrug that is converted into the active metab-
olite 7-ethyl-10-hydroxycamptothecin (SN-38), irino-
tecan, is potently toxic to topoisomerase I in vivo,
thus interrupting DNA replication in cancer cells
and resulting in a high rate of cell death. SN-38 is
further detoxified into its inactive metabolite, SN-
38G, through glucuronidation by the enzyme uridine
diphosphate glucuronosyltransferase (UGT) in the
liver. The glucuronidation of SN-38 to SN-38G is
the decisive step in the metabolism and detoxifica-
tion of irinotecan. The number of repeats in the
TATA box of the UGT1A1 promoter alters UGT1A1
activity, with six TA repeats representing the most
common allele of the UGT1A1 gene (UGT1A1*1,
wild-type) and seven TA repeats representing a vari-
ant allele (UGT1A1*28, mutant type).
Reduced gene transcription and expression of UGT1A1
are observed in individuals with the UGT1A1*28 variant;
consequently, reduced SN-38 glucuronidation and in-
creased irinotecan-related toxicity are well-established in
mCRC patients with the UGT1A1*28 variant. UGT1A1*28
is considered the main predictor of toxicity in mCRC
patients treated with irinotecan. The use of UGT1A1
genotyping as a predictive marker of irinotecan-induced
severe neutropenia or diarrhea has been approved by
the Food and Drug Administration of the United
States [2]. However, no predictive marker exists for
irinotecan-based chemotherapy in the treatment of
mCRC. Hence, we will evaluate the efficacy and
safety profile of FOLFIRI plus bevacizumab when the
irinotecan dosage is adjusted on the basis of the
blood UGT1A1 genotype through a prospective, mul-
ticenter, randomized controlled study.Objective
The primary objective is to implement a prospective,
randomized multicenter trial to evaluate the efficacy
of the FOLFIRI-plus-bevacizumab regimen with the
irinotecan dosage adjusted on the basis of the
UGT1A1 genotype as measured by the PFS at 1 year.
The secondary objective is to evaluate the efficacy of
the FOLFIRI-plus-bevacizumab regimen with the iri-
notecan dosage adjusted on the basis of the UGT1A1
genotype as measured by the objective response rate
(ORR) and toxicities, and finally to measure overall
survival (OS).
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On the basis of our previous study, we hypothesize
that patients with mCRC who receive pretherapeutic
UGT1A1 genotyping and subsequent irinotecan dose
escalation can achieve more favorable responses and
outcomes without a significant increase in toxicity
while using the FOLFIRI-plus-bevacizumab regimen.
Trial sites
The trial will be performed at 10 sites of the Colorectal
Cancer Consortium, part of the Grant of Biosignature in
Colorectal Cancers of the Academia Sinica in Taiwan.
Most of these sites have participated in previous ran-
domized controlled trials, and all of the centers are ad-
equately trained and prepared according to “Good
Clinical Practices” elaborated by the International Con-
ference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use to
participate in this trial.
Methods/Design
Description of the study
The details of this study are provided in Table 1. This
trial is a multicenter, randomized, controlled clinical
trial comparing UGT1A1 promoter polymorphism for
irinotecan dose escalation in mCRC patients adminis-
tered with FOLFIRI plus bevacizumab as the first-line
setting. The treatment administrators or patients areTable 1 Schedule of assessments
Assessment/Procedure
Available data will be collected; no additional diagnostic or monitoring

















Survival and tumor status/other anticancer treatmentnot masked to treatment allocation. In October 2014
400 mCRC patients were randomly enrolled into the
two groups. The study arms are described as follows
(Fig. 1):
Control group
The patients enrolled in the control group will be
treated with the conventionally recommended dose of
irinotecan, without UGT1A1 genotyping in advance.
The regimen for the treatment will consist of bevaci-
zumab (5 mg/kg as a 120-minute intravenous (IV) in-
fusion) on day 1, followed by irinotecan (180 mg/m2
as a 120-minute IV infusion), LV (200 mg/m2 as an IV
infusion over 2 hours), and 5-FU (2800 mg/m2 as an
IV infusion over a 46-hour period) and will be re-
peated biweekly. The control group will be UGT1A1
genotyped at the end of the trial.
Study group
The patients enrolled in this group were further divided
into three subgroups on the basis of their UGT1A1
genotypes:
Subgroup 1: UGT1A1 6TA/6TA genotype
The treatment regimen will comprise bevacizumab
(5 mg/kg as a 120-minute IV infusion) on day 1,
followed by irinotecan (180 mg/m2 as a 120-minute IV
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Fig. 1 Flowchart of this trial. The patients enrolled in the control group will be treated with the conventionally recommended dose of irinotecan
without UGT1A1 genotyping in advance. The patients enrolled in the study group will be divided further into three subgroups according to their
UGT1A1 genotypes; irinotecan dose escalation will be based on UGT1A1 genotyping
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a 46-hour period) and will be repeated biweekly. The
adverse effects (AEs), hematological or non-
hematological, will be observed after two cycles of each
dose of irinotecan. If the AEs are below grade 2, the
dose will be gradually escalated in steps of 30 mg/m2.
The estimated maximal dose of irinotecan is 260 mg/
m2.
Subgroup 2: UGT1A1 6TA/7TA genotype
The treatment regimen will comprise bevacizumab
(5 mg/kg as a 120-minute IV infusion) on day 1,
followed by irinotecan (180 mg/m2 as a 120-minuteIV infusion), LV (200 mg/m2 as an IV infusion over
2 hours), and 5-FU (2800 mg/m2 as an IV infusion
over a 46-hour period) and will be repeated
biweekly. The irinotecan dose will be increased in
increments of 30 mg/m2 (180, 210, 240) every two
cycles in the absence of grade 2 or worse AEs. The
maximal dose of irinotecan will be 240 mg/m2.
Subgroup 3: UGT1A1 7TA/7TA genotype
The treatment regimen will comprise bevacizumab
(5 mg/kg as a 120-minute IV infusion) on day 1,
followed by irinotecan (120 mg/m2 as a 120-minute
IV infusion), LV (200 mg/m2 as an IV infusion over
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over a 46-hour period) and will be repeated bi-
weekly. After two cycles of each irinotecan dose,
hematological and non-hematological AEs will be ob-
served. If the toxicities are below grade 2, the dose
will be gradually escalated in steps of 30 mg/m2.
The estimated maximal dose of irinotecan is
180 mg/m2.
Number of patients
A total of 400 mCRC patients histologically proved to
have adenocarcinoma in primary CRC, either metachro-
nous or synchronous, were enrolled in the study.
Randomization
The participants were randomized using sealed, opaque,
individually numbered envelopes, with the restriction of
selecting one per person. The envelopes contained data
sheets with information on group allocation and the
randomization number.
Target population/inclusion and exclusion criteria
Inclusion criteria
1. Patients had to be older than 20 years and have a
life expectancy of more than 3 months
2. Absence of other primary malignancies
3. Absence of central nervous system (CNS)
metastases
4. No major underlying diseases (such as
cardiovascular, cerebrovascular, malignant
hypertension, inadequate hematological function,
kidney, liver, or other major diseases) or any active
infections
5. mCRC confirmed in reports from pathologists or
radiologists according to the Response Evaluation
Criteria in Solid Tumors (RECIST) criteria
6. An Eastern Cooperative Oncology Group (ECOG)
performance status of 0–2
7. Subjects were willing to sign an informed consent
form
8. Subjects had to be at least 28 days from their
most recent surgery or have wounds that were
healed
9. Female participants who were not postmenopausal
(less than 12 months of amenorrhea) or surgically
sterile had to agree to use a highly effective
contraceptive method (i.e., with a failure rate of
<1 % per year, such as sexual abstinence, hormonal
implants, combined oral contraceptives, or a
vasectomized partner) during the treatment period
and for at least 6 months after the last dose of the
study drug. If it was not possible to use a highlyeffective contraceptive method, two barrier methods
were to be used
10. Male participants had to agree to use a highly
effective contraceptive method (i.e., with a failure
rate of <1 % per year, such as a vasectomy, sexual
abstinence, or a female partner using hormonal
implants or combined oral contraceptives) during
the trial and for a period of at least 6 months after
the last dose of the study drug. If it was not
possible to use a highly effective contraceptive
method, two barrier methods were to be used
Exclusion criteria
1. Patients who did not meet the inclusion criteria or
who were unwilling to participate
2. Prior or current antiangiogenic treatment
3. Treatment with any other investigational agent
within 28 days prior to enrollment in this study
4. Inadequate hematological function, as indicated by
all of the following:
Absolute neutrophil count <1.5 × 109/L
Platelet count <100 × 109/L
Hemoglobin <9 g/dL
5. Inadequate liver function, as indicated by all of the
following:
Total bilirubin ≥1.5 × upper limit of normal (ULN)
Aspartate transaminase (AST) and alanine
aminotransferase (ALT) ≥2.5 × ULN; in patients
with liver metastasis, AST and ALT ≥3.0 × ULN
Alkaline phosphatase ≥2.0 × ULN
6. Inadequate renal function, as indicated by all of the
following:
Serum creatinine >1.25 × ULN or calculated
creatinine clearance <50 mL/min
Urine dipstick for proteinuria at least 2+ unless a
24-hour urine protein <1 g of protein is
demonstrated
7. Inadequately controlled hypertension (defined as
systolic blood pressure >160 mmHg and/or diastolic
blood pressure >100 mmHg)
8. Prior history of hypertensive crisis or hypertensive
encephalopathy
9. History or evidence upon physical or neurological
examination of a CNS disease (e.g., seizures)
unrelated to cancer unless adequately treated with
standard medical therapy
10. Significant vascular disease (e.g., aortic aneurysm
requiring surgical repair or recent arterial
thrombosis) within 6 months of study enrollment
11. Any previous venous thromboembolism with less
than National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-
CTCAE) grade 3
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metastases, either by surgical or radiation
techniques, had to be completed more than
4 weeks prior to the first study treatment
13. History of hemoptysis of at least grade 2 (defined as
≥2.5 mL of bright-red blood per episode) within
1 month of study enrollment
14. History or evidence of inherited bleeding diathesis
or significant coagulopathy at the risk of bleeding
(i.e., in the absence of therapeutic anticoagulation)
15. Current or recent (within 10 days of study
enrollment) use of aspirin (>325 mg/day) or
clopidogrel (>75 mg/day); current or recent (within
10 days prior to first dose of bevacizumab) use of
therapeutic oral or parenteral anticoagulants or
thrombolytic agents for therapeutic purposes
Note: the use of full-dose oral or parenteral antico-
agulants was permitted as long as the international
normalized ratio (INR) or partial thromboplastin
time (PTT) was within therapeutic limits (accord-
ing to the medical standard of the institution) and
the patient had been on a stable dose of anticoagu-
lants for at least 2 weeks at the time of study
enrollment. The prophylactic use of anticoagulants
was allowed
16. Surgical procedure (including open biopsy, surgical
resection, wound revision, or any other major
surgery involving entry into a body cavity) or
significant traumatic injury within 28 days prior to
study enrollment or anticipation of the need for
major surgical procedure during the course of the
study
17. History of abdominal fistula, gastrointestinal (GI)
perforation, intra-abdominal abscess, or active GI
bleeding within 6 months prior to the first study
treatment
18. Serious, non-healing wound, active ulcer, or
untreated bone fracture
19. Known hypersensitivity to any component of
bevacizumab or any of the study drugs
20. Active infection requiring intravenous antibiotics at
the time of the first study treatment
21. Other malignancy within 5 years prior to study
enrollment, except for localized cancer in situ such
as basal or squamous cell skin cancer
22. Evidence of any other disease, neurological or
metabolic dysfunction, abnormal physical
examination finding, or laboratory finding leading
to a reasonable suspicion of a disease or
condition that contraindicated the use of any of
the study drugs, placed the patient at a higher
risk for treatment-related complications, or may
have affected the interpretation of the study
results23. Requirement for treatment with any medicinal
product that contraindicated the use of any of the
study drugs, may have interfered with the planned
treatment, affected patient compliance, or put the
patient at a high risk for treatment-related
complications
Genotyping
For analyzing constitutional gene polymorphisms, DNA
was first extracted from 4 mL of peripheral blood using a
PUREGENE® DNA isolation kit (Gentra Systems, Inc.,
Minneapolis, MN, USA). The genomic DNA from the
patients was then analyzed using direct sequencing to
determine the UGT1A1 promoter region genotype. The
primers used in this study were designed using primer 3
free software (http://primer3.wi.mit.edu). The sequences
of the forward and reverse primers were 5 -AGT-
CACGTGACACAGTCAAACA-3 and 5 -CTTTGCT
CCTGCCAGAGGTT-3 , respectively. The polymerase
chain reaction (PCR) reaction volume was 40 μL, and the
PCR conditions for the glutathione S-transferase pi 1
(GSTP1) were as follows: 94.0 °C for 5 minutes; 30 cycles
of denaturation for 30 seconds at 94.0 °C; annealing for
20 seconds at 67.5 °C; primer extension for 20 seconds at
72.0 °C; and final extension for 10 minutes at 72.0 °C. A
fragment analysis of the PCR products was conducted
to verify the genotypes by using the automated capil-
lary electrophoresis on the ABI PRISM 310 Genetic
Analyzer (Applied Biosystems, Foster City, CA, USA),
and the genotypes were analyzed using GeneScan and
Genotyper software (Applied Biosystems, Foster city,
CA, USA).
Interventions and trial timeline
The recruitment period of this study is expected to
last 24 months. The trial’s primary objective is ex-
pected to be attained within 36 months. The survival
data will be collected until death or a patient’s re-
quest for withdrawal. The end of the study will be




Responses are assessed radiologically by using com-
puted tomography scans, magnetic resonance images,
bone scans, or positron emission tomography scans,
with optimal responses being recorded. The time for
assessing the first response is typically after the sixth
cycle in patients who have received bevacizumab
combined with FOLFIRI chemotherapy. The responses
are classified by a radiologist according to RECIST
Version 1.1 [9].
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of all target lesions
2. A partial response (PR) is defined as at least a 30 %
decrease in the sum of the longest diameter, taking
the baseline sum’s longest diameter as a reference
point
3. Progressive disease is defined as at least a 20 %
increase in the sum of the longest diameter of the
target lesions, taking the smallest sum of the longest
diameters recorded before the patient started to
receive treatment as a reference. It can also be
defined as the identification of one or more new
lesions
4. Stable disease is defined as neither having sufficient
shrinkage to quality as a PR nor a sufficient increase
to qualify as a progressive disease
5. PFS is defined as the time from the beginning of
treatment until the first documentation of
progression, regardless of the patient’s treatment
status
6. OS is defined as the time from the beginning of
treatment until the date of a death event or the last
recorded date of follow-up.Safety outcome measures
The AEs will be assessed in each cycle using the NCI-
CTCAE 4.0 (http://ctep.cancer.gov/reporting/ctc.html,).
AEs over grade 2 will be noted, such as the following:
1. Hypertension at least grade 3
2. Proteinuria at least grade 3
3. GI perforation, abscesses, and fistulae (any grade)
4. Wound healing complications at least grade 3
5. Hemorrhage at least grade 3 (CNS bleeding of any
grade; hemoptysis at least grade 2)
6. Arterial thromboembolic events (any grade)
7. Venous thromboembolic events at least grade 3
8. Posterior reversible encephalopathy syndrome (any
grade)
9. Congestive heart failure at least grade 3
10. Non-GI fistula or abscess at least grade 2
11. Cases of an elevated ALT or AST with or without
elevated bilirubin (total bilirubin ≥2 mg/dL)
12. Suspected transmission of an infectious agent by
the study drugParagraph of dose reduction of irinotecan and
stopping rule
Dose escalation was terminated if grade 3 or 4 AEs
occurred, and when such grade 3 or 4 AEs did occur, the
patients were treated subsequently with the highest dose of
irinotecan they were able to tolerate previously. The treat-
ment was stopped in the event of patient withdrawal,disease progression, or unacceptable toxic effects (non-
hematological grade 4 toxicity, no recovery from grade 3
toxicity after two dose adjustments or non-recovery after a
2-week treatment delay). Any dose reduction was
permanent.
Statistical methods
Determination of sample size
This study enrolled approximately 400 mCRC patients.
It is anticipated that the PFS will increase by 2.8 months
compared with the PFS expected when using the con-
ventional irinotecan dose of 180 mg/m2; hence, these
parameters were selected for calculating the study
power. An initial power calculation suggested that a
minimum of 200 patients were required in each group
to achieve statistical significance with a power of 80 % at
a 5 % significance level. It is estimated that approxi-
mately 20 % of the 400 mCRC patients will fail to
complete the study. The enrolled patients were UGT1A1
genotyped before therapy and then randomly assigned to
one of the two groups, the control and study groups.
The control group includes mCRC patients who receive
the conventional FOLFIRI regimen. The patients in the
study group will be provided dose escalation depending
on the results of their genotyping.
All of the data were analyzed using the Statistical Pack-
age for the Social Sciences Version 17.0 software (SPSS,
Inc., Chicago, IL, USA). The descriptive variables of the
patient characteristics and toxicities were calculated dir-
ectly from the database. A chi-squared test or Fisher’s
exact test was used to compare the toxicities and re-
sponses between the two groups. The PFS and OS were
calculated and plotted according to the Kaplan-Meier
method and were compared using a log-rank test. A prob-
ability of less than 0.05 was considered statistically
significant.
Analysis of primary endpoints
The PFS will be analyzed to examine superiority between
the two groups.
Analysis of secondary endpoints
The efficacy of the bevacizumab-plus-FOLFIRI regimen
with the irinotecan dosage adjusted on the basis of the
UGT1A1 genotype, as measured using the ORR and toxic-
ities, will be evaluated. This ORR will include the response
rates (confirmed complete and partial responders), esti-
mated difference in response rates, and associated 95 %
confidence intervals.Ethical approval
In compliance with the Helsinki Declaration, this
study was approved by the Institutional Review Board
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Medical University, Kaohsiung, Taiwan. (IRB number:
KMUHIRB-20130020). We will obtain informed con-
sent from each participant.
Discussion
Irinotecan is converted into SN-38 by a carboxylesterase
and finally metabolized by the enzyme UGT (predomin-
antly by the UGT1A1 isoenzyme). Recently, Marcuello
et al. [10] conducted a genotype-directed dose-finding
study on irinotecan in combination with fluorouracil/LV
as a first-line treatment for advanced mCRC.
Genotyping and sequencing data have led to the
discovery of over 100 variants within the promoter re-
gions and coding sequence of the UGT1A genes [11].
Many of these variants exhibit allele frequencies of up to
40–50 % in the general population, which are in linkage
disequilibrium. However, a few variants are of sufficient
frequency in the general population to be classified as
polymorphisms [11–13]. Polymorphisms lead to differ-
ent degrees of transcriptional and functional alterations,
which may reduce UGT activity and result in the path-
ology of the affected individuals [11, 14].
We conducted the current study, based on our previ-
ous retrospective investigation published in 2014 [8], of
which we had the prospective, randomized trial to obtain
Institutional Review Board (IRB) approval in Taiwan. At
that time there was no relevant information regarding
UGT1A1*6 genotyping that could be used for directing
dose escalation of irinotecan (trade name: Camptosar®
other name: Camptothecin-11(CPT-11)) in Taiwanese
mCRC patients. In fact, one recent study published by
Kim et al. in 2015 [15], Patients were genotyped for
UGT1A1 and stratified according to the number of de-
fective alleles (DA; *28 and *6) wherein they showed that
the recommended doses were 300 (0 DA), 270 (1 DA)
and 150 (0 DA) mg/m2. Conversely, there were no sig-
nificant differences in the efficacy or toxicity of FOLFIRI
between patients with the UGT1A1*1/*1 genotype and
those with the UGT1A1*1/*6 or *1/*28 genotypes [16].
Additionally, Maeda et al. had demonstrate that
UGT1A1*6 A/A polymorphism were not statistically dif-
ferent between the Caucasian population and Asian pop-
ulations (P value = 1.0) [17].
Patients with homozygous polymorphism of the
UGT1A1 promoter (UGT1A1*28) were more frequently
associated with severe toxicity following irinotecan treat-
ment. The genotypes of the promoter polymorphism of
the UGT1A1 gene in our patients were either UGT1A1 6/
6 or UGT1A1 6/7. Individuals who are homozygous for
the UGT1A1*28 allele are at an increased risk of toxicity
following the initiation of FOLFIRI treatment; a low initial
dose should be considered for patients known to be
homozygous for the UGT1A1*28 allele (seven repeats).Heterozygous patients (carriers of one variant allele and
one wild-type allele, which results in intermediate
UGT1A1 activity) may be at an increased risk of toxicity;
however, clinical results were variable, and such patients
could tolerate the normal starting dose [18]. Furthermore,
the possible role of bevacizumab as a protective agent
against irinotecan toxicity in these patients should be in-
vestigated. The addition of bevacizumab improved the
pathological response and protection against hepatic injur-
ies in patients treated with oxaliplatin-based chemother-
apy for colorectal liver metastases [19]. This trial is
performed to demonstrate the prognostic advantage of
UGT1A1 genotyping and irinotecan dose escalation before
systemic chemotherapy to patients with mCRC.
In our previous study, a combination of bevacizumab
and FOLFIRI as a first-line therapy for mCRC patients
was retrospectively demonstrated to have a favorable re-
sponse rate and acceptable toxicity. Nearly 70 % of the
patients (55 of 79) with mCRC who had undergone
pretherapeutic UGT1A1 genotyping and received an
escalated dose of irinotecan responded clinically to
bevacizumab-plus-FOLFIRI chemotherapy [8]. There-
fore, we are prospectively conducting a clinical trial to
demonstrate that irinotecan dose escalation can achieve
more favorable responses and outcomes without a sig-
nificant increase in toxicities while using the FOLFIRI-
plus-bevacizumab regimen. The use of novel genomic
DNA analysis in our current study can achieve more fa-
vorable clinical outcomes for mCRC patients.
Trial status
The trial started in January 2015 and is expected to fin-
ish in December 2017. Sixty-eight patients, including 34
patients in the study group and 34 patients in the con-
trol group, had been enrolled into the study by the end
of the November 2015.
Abbreviations
5-FU: 5-fluorouracil; AEs: adverse effects; ALT: alanine aminotransferase;
AST: aspartate transaminase; CNS: central nervous system; CRC: colorectal
cancer; ECOG: Eastern Cooperative Oncology Group; FOLFIRI: chemotherapy
of 5-fluorouracil/leucovorin/irinotecan; LV: leucovorin; mCRC: metastatic
colorectal cancer; NCI-CTCAE: National Cancer Institute-Common
Terminology Criteria; ORR: objective response rate; OS: overall survival;
PFS: progression-free survival; PR: partial response; RECIST: Response
Evaluation Criteria in Solid Tumors; SN-38: active metabolite, 7-ethyl-10-
hydroxycamptothecin, which is potently toxic to topoisomerase I;
ULN: upper limit of normal; UGT: uridine diphosphate
glucuronosyltransferase; UGT1A1: uridine diphosphate
glucuronosyltransferase 1A1.
Competing interests
The authors declare no competing interests.
Authors’ contributions
All of the authors participated in the trial design. YS wrote the study
protocol and helped to draft the manuscript. HL contributed to the statistical
methods and the analysis. CW carried out the molecular genetic studies and
immunoassays. JH participated in the design and coordination of the study.
YW conceived of the study and participated in its design. CC participated in
the design and coordination of the study. HC participated in the sequence
alignment. YC participated in the sequence alignment. CY participated in the
sequence alignment. JY critically revised the manuscript. All of the authors
read and approved the final version of the manuscript.
Acknowledgements
This work is supported by grants from Pfizer (WI186515), Roche (ML29373),
the Excellence for Cancer Research Center Grant, and the Taiwan Ministry of
Health and Welfare (MOHW105-TDU-B-212-134005)and Health and welfare
surcharge of tobacco products, in addition to grants from Kaohsiung Medical
University Hospital (KMUH103-3 M03, KMUH104- 4 M27, KMUH104-4 R19,
KMUHS10418), the Center for Biomarkers and Biotech Drugs of Kaohsiung
Medical University (KMU-TP103C00, KMU-TP103C03, KMU-TP103C07, KMU-
TP103H11), and the Grant of Biosignature in Colorectal Cancers from the
Academia Sinica of Taiwan.
Author details
1Division of Trauma, Department of Surgery, Kaohsiung Medical University
Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 2Division of
Gastroenterology and General Surgery, Department of Surgery, Kaohsiung
Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
3Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan. 4Division of General Surgery Medicine,
Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung, Taiwan. 5Graduate Institute of Medicine,
College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
6Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung
Medical University, Kaohsiung, Taiwan. 7Division of Colorectal Surgery,
Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung, Taiwan. 8Division of Colorectal Surgery,
Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung,
Taiwan. 9Department of Surgery, Tainan Municipal Hospital, Tainan, Taiwan.
10Colon and Rectal Surgery, Tainan Sin-Lau Hospital, Tainan, Taiwan.
11Division of Hematology-Oncology, Department of Internal Medicine,
Cathay General Hospital, Taipei, Taiwan. 12Division of Colon and Rectal
Surgery, Department of Surgery, Tri-Service General Hospital, National
Defense Medical Center, Taipei, Taiwan. 13Division of Gastroenterology,
Department of Internal Medicine, Kaohsiung Medical University Hospital,
Kaohsiung Medical University, Kaohsiung, Taiwan. 14Department of Internal
Medicine, Faculty of Medicine, College of Medicine, Kaohsiung Medical
University, Kaohsiung, Taiwan. 15Center for Biomarkers and Biotech Drugs,
Kaohsiung Medical University, Kaohsiung, Taiwan.
Received: 21 October 2015 Accepted: 4 January 2016
References
1. Ishida H, Fujita K, Akiyama Y, Sunakawa Y, Yamashita K, Mizuno K, et al.
Regimen selection for first-line FOLFIRI and FOLFOX based on UGT1A1
genotype and physical background is feasible in Japanese patients with
advanced colorectal cancer. Jpn J Clin Oncol. 2011;41:617–23.
2. Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, et al.
Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their
haplotypes on the outcome of metastatic colorectal cancer patients treated
with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 2009;27:2457–65.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al.
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Irinotecan Study Group. N Engl J Med. 2000;343:905–14.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P,
et al. Irinotecan combined with fluorouracil compared with fluorouracil
alone as first-line treatment for metastatic colorectal cancer: a multicentre
randomised trial. Lancet. 2000;355:1041–7.
5. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W,
et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
6. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A,
et al. Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 2009;360:1408–17.
7. Peeters M, Price T. Biologic therapies in the metastatic colorectal cancer
treatment continuum – applying current evidence to clinical practice.
Cancer Treat Rev. 2012;38:397–406.
8. Lu CY, Huang CW, Hu HM, Tsai HL, Huang CM, Yu FJ, et al. Prognostic
advantage of irinotecan dose escalation according to uridine diphosphate
glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic
colorectal cancer treated with bevacizumab combined with 5-fluorouracil/
leucovorin with irinotecan in a first-line setting. Transl Res. 2014;164:169–76.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
et al. New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of Canada.
J Natl Cancer Inst. 2000;92:205–16.
10. Marcuello E, Páez D, Paré L, Salazar J, Sebio A, del Rio E, et al. A genotype-
directed phase I-IV dose-finding study of irinotecan in combination with
fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer.
Br J Cancer. 2011;105:53–7.
11. Wang M, Sun DF, Wang S, Qing Y, Chen S, Wu D, et al. Polymorphic
expression of UDP-glucuronosyltransferase UGTlA gene in human colorectal
cancer. PLoS One. 2013;8:e57045.
12. Maitland ML, Grimsley C, Kuttab-Boulos H, Witonsky D, Kasza KE, Yang L,
et al. Comparative genomics analysis of human sequence variation in the
UGT1A gene cluster. Pharmacogenomics J. 2006;6:52–62.
13. Thomas SS, Li SS, Lampe JW, Potter JD, Bigler J. Genetic variability, haplotypes,
and htSNPs for exons 1 at the human UGT1A locus. Hum Mutat. 2006;27:717.
14. Tang KS, Chiu HF, Chen HH, Eng HL, Tsai CJ, Teng HC, et al. Link between
colorectal cancer and polymorphisms in the uridine-
diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J
Gastroenterol. 2005;11:3250–4.
15. Kim KP, Hong YS, Lee JL, Bae KS, Kim HS, Shin JG, et al. A phase I study of
UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean
patients with metastatic colorectal cancer receiving FOLFIRI. Oncology.
2015;88:164–72.
16. Sunakawa Y, Ichikawa W, Fujita K, Nagashima F, Ishida H, Yamashita K, et al.
UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and
toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Cancer Chemother Pharmacol. 2011;68:279–84.
17. Maeda H, Hazama S, Shavkat A, Okamoto K, Oba K, Sakamoto J, et al.
Differences in UGT1A1, UGT1A7, and UGT1A9 polymorphisms between
Uzbek and Japanese populations. Mol Diagn Ther. 2014;18:333–42.
18. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan
plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of
metastatic colorectal cancer: updated results from the BICC-C study. J Clin
Oncol. 2008;26:689–90.
19. Ribero D, Wang H, Donadon M, Zorzi D, Thomas MB, Eng C, et al.
Bevacizumab improves pathologic response and protects against hepatic
injury in patients treated with oxaliplatin-based chemotherapy for colorectal
liver metastases. Cancer. 2007;110:2761–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Yeh et al. Trials  (2016) 17:46 Page 9 of 9
